Today, Taysha Gene Therapies shared several exciting updates on their REVEAL Phase 1/2 clinical trial of investigational gene therapy TSHA-102:
- The study will now expand to include adolescent and adult patients in the U.S. (age 12+ protocol).
- The dosing of the first cohort (low dose) is complete in the adult study in Canada with clinical data on this cohort is expected in Q1 2024. The IDMC approved moving forward with dosing the first patient in the high dose cohort (expected Q2 2024).
- The IDMC also approved the dosing of the 2nd patient in the U.S./United Kingdom pediatric study (expected Q1 2024).
Taysha also shared a letter with answers to frequently asked questions with patient advocacy groups. To view the letter, CLICK HERE.
IRSF is with you every step of the way. For the most up-to-date information on this and all other research and clinical trials in the Rett pipeline, click here. Questions? Email us at [email protected].